亚宝药业：拟向同享科技出售太原制药62%股权

Core Viewpoint - The company plans to sell 62% of its subsidiary Taiyuan Pharmaceutical to Shanxi Tongxiang Times Technology for a transaction price of 87.1887 million yuan, which will enhance asset operation efficiency and provide funding support for business expansion [1] Group 1 - The transaction will result in Shanxi Tongxiang holding 95% of Taiyuan Pharmaceutical, while the company retains 5% [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements after the transaction [1] - The company estimates that the transaction will increase its total profit by approximately 59 million yuan in 2025 [1]